Btk inhibition treats TLR7/IFN driven murine lupus

Btk inhibition treats TLR7/IFN driven murine lupus

Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 164(2016) vom: 09. März, Seite 65-77
1. Verfasser: Bender, Andrew T (VerfasserIn)
Weitere Verfasser: Pereira, Albertina, Fu, Kai, Samy, Eileen, Wu, Yin, Liu-Bujalski, Lesley, Caldwell, Richard, Chen, Yi-Ying, Tian, Hui, Morandi, Federica, Head, Jared, Koehler, Ursula, Genest, Melinda, Okitsu, Shinji L, Xu, Daigen, Grenningloh, Roland
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Bruton's tyrosine kinase Interferon Lupus TLR7 Autoantibodies Immunosuppressive Agents Interferon Type I Protein Kinase Inhibitors mehr... TLR7 protein, human Terpenes Toll-Like Receptor 7 pristane 26HZV48DT1 Protein-Tyrosine Kinases EC 2.7.10.1 Agammaglobulinaemia Tyrosine Kinase EC 2.7.10.2 BTK protein, human Btk protein, mouse
LEADER 01000naa a22002652 4500
001 NLM256938849
003 DE-627
005 20231224181734.0
007 cr uuu---uuuuu
008 231224s2016 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2016.01.012  |2 doi 
028 5 2 |a pubmed24n0856.xml 
035 |a (DE-627)NLM256938849 
035 |a (NLM)26821304 
035 |a (PII)S1521-6616(16)30013-4 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Bender, Andrew T  |e verfasserin  |4 aut 
245 1 0 |a Btk inhibition treats TLR7/IFN driven murine lupus 
264 1 |c 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 18.07.2016 
500 |a Date Revised 02.12.2018 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved. 
520 |a Bruton's tyrosine kinase (Btk) is expressed in a variety of immune cells and previous work has demonstrated that blocking Btk is a promising strategy for treating autoimmune diseases. Herein, we utilized a tool Btk inhibitor, M7583, to determine the therapeutic efficacy of Btk inhibition in two mouse lupus models driven by TLR7 activation and type I interferon. In BXSB-Yaa lupus mice, Btk inhibition reduced autoantibodies, nephritis, and mortality. In the pristane-induced DBA/1 lupus model, Btk inhibition suppressed arthritis, but autoantibodies and the IFN gene signature were not significantly affected; suggesting efficacy was mediated through inhibition of Fc receptors. In vitro studies using primary human macrophages revealed that Btk inhibition can block activation by immune complexes and TLR7 which contributes to tissue damage in SLE. Overall, our results provide translational insight into how Btk inhibition may provide benefit to a variety of SLE patients by affecting both BCR and FcR signaling 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Bruton's tyrosine kinase 
650 4 |a Interferon 
650 4 |a Lupus 
650 4 |a TLR7 
650 7 |a Autoantibodies  |2 NLM 
650 7 |a Immunosuppressive Agents  |2 NLM 
650 7 |a Interferon Type I  |2 NLM 
650 7 |a Protein Kinase Inhibitors  |2 NLM 
650 7 |a TLR7 protein, human  |2 NLM 
650 7 |a Terpenes  |2 NLM 
650 7 |a Toll-Like Receptor 7  |2 NLM 
650 7 |a pristane  |2 NLM 
650 7 |a 26HZV48DT1  |2 NLM 
650 7 |a Protein-Tyrosine Kinases  |2 NLM 
650 7 |a EC 2.7.10.1  |2 NLM 
650 7 |a Agammaglobulinaemia Tyrosine Kinase  |2 NLM 
650 7 |a EC 2.7.10.2  |2 NLM 
650 7 |a BTK protein, human  |2 NLM 
650 7 |a EC 2.7.10.2  |2 NLM 
650 7 |a Btk protein, mouse  |2 NLM 
650 7 |a EC 2.7.10.2  |2 NLM 
700 1 |a Pereira, Albertina  |e verfasserin  |4 aut 
700 1 |a Fu, Kai  |e verfasserin  |4 aut 
700 1 |a Samy, Eileen  |e verfasserin  |4 aut 
700 1 |a Wu, Yin  |e verfasserin  |4 aut 
700 1 |a Liu-Bujalski, Lesley  |e verfasserin  |4 aut 
700 1 |a Caldwell, Richard  |e verfasserin  |4 aut 
700 1 |a Chen, Yi-Ying  |e verfasserin  |4 aut 
700 1 |a Tian, Hui  |e verfasserin  |4 aut 
700 1 |a Morandi, Federica  |e verfasserin  |4 aut 
700 1 |a Head, Jared  |e verfasserin  |4 aut 
700 1 |a Koehler, Ursula  |e verfasserin  |4 aut 
700 1 |a Genest, Melinda  |e verfasserin  |4 aut 
700 1 |a Okitsu, Shinji L  |e verfasserin  |4 aut 
700 1 |a Xu, Daigen  |e verfasserin  |4 aut 
700 1 |a Grenningloh, Roland  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 164(2016) vom: 09. März, Seite 65-77  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:164  |g year:2016  |g day:09  |g month:03  |g pages:65-77 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2016.01.012  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 164  |j 2016  |b 09  |c 03  |h 65-77